米非司酮配伍米索前列醇联合利凡诺用于中孕引产的观察.doc

《米非司酮配伍米索前列醇联合利凡诺用于中孕引产的观察.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、米非司酮配伍米索前列醉联合利凡诺用于屮孕引产的观察作者单位：409000重庆市黔江区生殖健康屮心通讯作者：庞平【摘要】目的探讨米非司酮配伍米索前列醉联合利凡诺用于屮孕引产的临床效果。方法将2010年1〜12月笔者所在生殖健康屮心收治的要求终止妊娠的屮孕（20〜27周孕）孕妇280例，随机分为两纟股观察纟fl入院后经腹羊膜腔内注射利凡诺100mg,同时口服米非司酮75mg,12h1次，总量150mg,在服完最后75mg米非司酮后1h口服米索前列醇0.6mg,并经阴道后穹隆放置米索前列醉0.2mg,4h后宫缩弱或未启动、宫颈软化不佳者可经阴道重复给药0.2mg。对照组入院后单一经腹羊膜腔内注射

2、利凡诺100mgo结果对照组屮1例孕妇行二次羊膜腔穿刺注药引产成功，观察组无类似情况，联合用药纽从注药至宫缩开始时间及从宫缩开始至胎盘娩出时间均明显缩短（P<0・05）,胎盘胎膜残留、产麻2h阴道流血量及宫颈撕裂伤的发生率均较对照组明显减少（P<0.05）o结论米非司酮配伍米索前列醇联合利凡诺羊膜腔内注射用于屮孕引产使引产总产稈缩短，降低了引产并发症的发生率，是一种值得推广的中孕引产方法。【关键词】米非司酗；米索前列醇；利凡诺；屮孕引产ClinicaloverviewofMifepristonecompatiblewithMisoprostolandRivanolininducedlabo

3、rofmiddlepregnancyPANGPing,ZHANGChun-hua,ZHANGYu-chang,WEIQun.ReproductiveHealthCcnterofQianjiangDistrictofChongqing,Chongqing409000,China【Abstract】ObjectiveToinvestigotetheclinicaleffectofmifepristonecompatiblewithmisoprostolandrivanolininducedlaborofmiddlepregnancy・MethodsReview280casesofinduced

4、laborwomenofmiddlepregnancy（with20-27weekspregnancy）inourcenterfromJanuary,2010toDecember,2010.Allthesepregriantwomenwererandomlydevicledintotwogroups:Theobservationgroupwasadministered100mgofrivanolbyintra-amnioticinjectionandtakenorally75mgofmifepristone/12honanemptystomachfor24h・Onehourafterthe

5、lasttakingmifepristone,0・6mgofmisoprostolwastakenorallybyobservationgroupand0.2mgofmisoprostolwereplacedinposteriorfornixofvaginaofthesewomen.Afterfourhours,thewomenwithuterineatonyorcervixeffacementpoorcanbere-administerecl0.2mgofmisoprostolbyvagina.Thecontrolgroupwasonlyadministered100mgofrivano

6、lbyintra-amnioticinjection.ResultsOnlyonecaseofthecontrolgroupwassuccessfulininductionbysecondintra-amnioticinjection.Inobservationgroup,thetimefromthelastadministrationtothebeginningofliterinecontractionorfromthebeginningofuterinecontractiontofetusdeliverywassignificantlydecreasedwithrespecttothe

7、controlgroup（P〈0.05）.Theincidenceofretaineclplacenta,vaginableedingvolumnwithin2hoursafterdeliveryandcervicallacerationwasremarkedlyinclinedwithrespecttothecontrolgroup（P<0.05）.ConclusionMifepristonecompatiblewit